Bain Capital Acquires Evident

Bain Capital has acquired Evident, a leading provider of software and services for the healthcare industry.

Evident is a well-established company with a strong track record of innovation and customer satisfaction.

The acquisition is a significant milestone for both companies, marking a new chapter in their journey together.

Bain Capital Private Equity has a long history of partnering with management teams to build great companies and help them thrive since its founding in 1984.

The firm has made primary or add-on investments in more than 1,100 companies since its inception. Bain Capital has 23 offices on four continents.

Bain Capital Private Equity's global team of over 280 investment professionals creates value for its portfolio companies through its global platform and depth of expertise in key vertical industries.

The firm has a global platform in Healthcare and Life Science with a similar depth in pathology and life science instrumentation.

Bain Capital has invested in companies such as II-VI, Kioxia, Sensata, and NXP, supporting the growth and innovation of industrial technology companies globally.

On a similar theme: Is Bain Capital a Private Equity Firm

The investment in Evident is expected to be completed in the first quarter of 2023, subject to regulatory approvals and closing conditions.

Bain Capital's global resources and team's accumulated experience will be committed to assist Evident to realize attractive growth opportunities and create value for all stakeholders.

Evident will continue over 100 years of innovation in imaging, instrumentation, and measurement solutions, underpinned by deep and broad customer relationships, best-in-class technology, and differentiated capabilities in R&D and precision manufacturing.

Bain Capital Private Equity has partnered closely with management teams to provide the strategic resources that build great companies and help them thrive since its founding in 1984.

The firm has a deep understanding of Evident's business value and growth potential, particularly appreciating its entrepreneurial culture.

Bain Capital has a shared platform that leverages the firm's global resources to capture opportunities in strategic areas of focus, managing approximately $160 billion in total assets.

Check this out: Growth Capital Company

Olympus Corporation and Evident, a wholly-owned subsidiary of Olympus, agreed to transfer Evident to Bain Capital Private Equity. This transfer is expected to be completed on January 4, 2023, subject to regulatory approvals and closing conditions.

Evident conducts business in fields of life science and industrial applications, which are underpinned by deeply rooted and strong demand from the global market. Microscopes used for life science support a broad range of academic and clinical research areas, pathology diagnostic services, as well as the recently growing demand for drug discovery and fertility treatment.

Olympus concluded that it would be in its best interest to transfer all shares of Evident to Bain Capital in order to allow Evident to develop its business with more agile and flexible decision-making based on market needs. This will lead to further growth and the development of more innovative solutions for Evident's customers.

Evident's Industrial solutions range from microscopes used in the expanding semiconductor sector and electronic components markets to industrial videoscopes and fiberscopes, non-destructive testing equipment, and X-ray fluorescence analyzers used in industrial applications. These wide-ranging applications include automotive, aviation, metal manufacturing, power generation, precious metal, and several other manufacturing and inspection markets.

Take a look at this: Emerging Markets Private Equity